Screener
Rapport Therapeutics, Inc. RAPP Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity | ||
| Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; zero shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025; 47,955,079 shares and 47,772,567 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 48 | 48 |
| Additional paid-in capital | 735,848 | 719,287 |
| Accumulated other comprehensive income (loss) | (1,270) | 546 |
| Accumulated deficit | (311,700) | (235,228) |
| Total stockholders’ equity | 422,926 | 484,653 |
| Total liabilities and stockholders’ equity | $458,982 | $512,431 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s total equity?
- Rapport Therapeutics, Inc. (RAPP) reported total equity of $422.93M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s total equity changed year-over-year?
- Rapport Therapeutics, Inc.'s total equity increased by 60.5% year-over-year, from $263.51M to $422.93M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s total equity?
- Over 3 years (2022 to 2025), Rapport Therapeutics, Inc.'s total equity has grown at a 263.8% compound annual growth rate (CAGR), from -$10.06M to $484.65M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Rapport Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude